Skip to main content
. 2021 Apr 25;7(2):139–153. doi: 10.3390/tomography7020013

Figure 2.

Figure 2

Change in regional 18F uptake in response to dasatinib treatment in mCRPC bone metastases measured by SUVpeak, SUVmax. No significant changes were seen in normal bone. Diff = Scan2—Scan1; Pval = p-value. * Difference = Δ in tumor bone—Δ in normal bone.